German developer of products in molecular biology, Sygnis has launched its TruePrime Liquid Biopsy Kit to detect, analyse and monitor the early stages of tumours.
The liquid biopsy kit is based on Sygnis’ TruePrime technology which features a combination of polymerase TthPrimPol and Phi29 DNA polymerase in which TthPrimPol synthesises the primers needed for Phi29 DNA pol on the fly, which amplifies the genomic DNAs.
The strand displacement capacity of the Phi29 polymerase enables TthPrimPol to produce new primers on the displaced strands that are extended by Phi29 DNA pol, resulting in exponential isothermal DNA amplification without the need of any synthetic random primers.
Sygnis co-CEO and CSO Heikki Lanckriet said: “TruePrime Liquid Biopsy is unique in that it selectively amplifies cancerous DNA in blood samples.
“Moreover the TruePrime DNA amplification technology provides higher quality DNA as it amplifies more accurately with less bias than any other DNA amplification technology currently available.
“It is also 1000 times more sensitive than any other multiple displacement amplification (MDA) technique currently availableon the market.
"Due to these valuable properties the technology is poised to make a momentous impact in the field of oncology research and cancer diagnosis.”
In addition to becoming a valuable tool in oncology research The TruePrime technology can be leveraged in the field of precise medicine as well as in the diagnosis and monitoring of cancer.